Theronostics and radiopharmaceuticals are today’s buzzwords in advances to treat prostate cancer.
BAMF Health Chief Medical Advisor Dr. Harshad Kulkarni explains, theronostics is a promising approach using radiopharmaceuticals to both image and treat cancer by targeting a specific protein.
“It is a simple injection of a radioactive drug which kills cancer cells from inside out and this is for the form of prostate cancer that has spread beyond the prostate so metastatic prostate cancer.”
Theronostics are now approved for use in patients’ pre-chemotherapy.
“That is a major breakthrough that has happened just in the last two months.”
Kulkarni says the most important factor in treating prostate cancer remains early detection.
Testing is recommended when men reach age 50 with a simple blood sample. Now there’s another option.
“Molecular imaging. We inject a radioactive drug that binds specifically with prostate cancer cells, so it enables the earliest and most accurate detection.”
BAMF Health is partnering with Gilda’s Club Grand Rapids to hold a discussion on advances in prostate cancer care Monday June 2, 6PM at the Gilda’s Clubhouse or via Zoom.
The public is welcome to attend, details at gildasclubgr.org.
